Six weeks in diabetic mice: an implant that turns excess sugar into something you pass out
What happened
A team at ETH Zurich has built a small implant that lowers blood sugar using electricity instead of a drug, and tested it successfully in diabetic mice. The idea is unusual. Most diabetes treatments work by changing how the body handles glucose - insulin to move it into cells, or medicines that reduce how much the liver releases or how much the gut absorbs. This device does something different. It chemically converts excess glucose into a substance called gluconate, which the body then removes in urine. The conversion happens on a catalyst: graphite felt coated in tiny clusters of gold, which are themselves coated in platinum particles. Run a small current through it in the presence of glucose, and the reaction takes place. The clever part is the control system. A glucose sensor measures sugar levels in the tissue and sends readings by Bluetooth to a smartphone or smartwatch. If levels are too high, the phone switches the implant on. When glucose comes back down into the target range, it switches off. Researchers call this closed-loop control - the system watches, acts, and stops on its own. The implant has no battery. It receives power wirelessly at a radio frequency of 13.56 MHz. In one laboratory test, the catalyst converted glucose in five litres of nutrient solution - roughly the volume of blood circulating in an adult. In diabetic mice, the device regulated blood sugar precisely and the animals lost weight. It kept working reliably over six weeks and was well tolerated, with no tissue damage reported from electrical or heat effects. The study, 'Wireless electrocatalytic closed-loop system for drug-free management of diabesity', was published in the journal Science. The senior author is Professor Martin Fussenegger of ETH Zurich's Department of Biosystems Science and Engineering in Basel.
Why this matters
Type 2 diabetes is one of the most common long-term conditions in the UK, and managing it is relentless. Tablets, sometimes injections, finger-prick tests or a sensor, repeat prescriptions, reviews, and a constant background awareness of food and timing. Anything that genuinely reduces that daily load would matter a great deal to a lot of people. There is also a specific problem this approach sidesteps. Insulin and some other treatments can push blood sugar too low - hypoglycaemia - which is unpleasant at best and dangerous at worst. Professor Fussenegger made the point that this catalyst 'only activates when glucose levels are too high'. A system that physically cannot do anything unless there is surplus sugar to work on has a different safety profile from one that adds a hormone to the bloodstream. The word in the paper's title - 'diabesity' - points at the other reason researchers are interested. Type 2 diabetes and obesity often travel together, and the mice in this study lost weight as well as regulating their blood sugar. A single approach touching both would be significant. And 'drug-free', in the paper's phrasing, means no new medicine to absorb, metabolise or interact with everything else someone is taking. For anyone managing several conditions at once, that is a real advantage - in principle.
What the evidence actually says
Here is the part that matters most, and it should be read before anything else in this article is taken as hope. This device has not been tested in a single human being. It was tested in a laboratory solution and in diabetic mice. That is it. The researchers say so themselves, and they are clear that further research is needed to establish whether it is safe and effective in people. The next step they describe is developing it into a medical device that could then enter clinical testing. The distance between 'worked in mice' and 'available to patients' is enormous, and most things that work in mice do not survive it. Mice are small, short-lived, genetically similar to one another, and living in controlled conditions. People are none of those things. A six-week result in a mouse is not a six-week result in a person, and six weeks is itself very short for something intended to be implanted for years. There are also practical questions the study does not answer. The results reported in the news release give no numbers for how far blood sugar fell or how much weight the mice lost - just that both happened. Without figures, the size of the effect is unknown. Longer-term questions are open too. The catalyst relies on gold and platinum surfaces; how those hold up inside a body over years is not established here. Nor is what happens if the sensor, the Bluetooth link or the phone fails - a closed loop is only as reliable as every part of it. And a system that depends on a smartphone depends on the person having one, charged, nearby. None of that makes the work unimportant. It is published in Science, which is among the most selective journals there is, and the engineering is genuinely novel. It is early-stage research that has cleared an early-stage bar. That is all it is, and that is still worth knowing.
Qurexa perspective
We are a pharmacy delivery service, so we will say the obvious thing: nothing here changes how anyone should manage diabetes today. What we see in practice is that the hard part of diabetes is rarely the science. It is the routine. Tablets that need taking at the right time, prescriptions that need reordering before they run out, and the stretch between a review appointment and the next one. People do not usually stop managing their condition on purpose; it slips, because life is busy and the admin is constant. That is the gap our prescription delivery and medication adherence support are built for, and it is the same gap this research is ultimately aiming at from a different direction - reducing how much work a condition demands from the person who has it. Until an approach like this has been through human trials and approval, the best available tool is still the treatment plan you already have, taken as prescribed. If keeping up with it is the difficult bit, that is a solvable problem, and worth raising with your pharmacist.
Practical advice
**Do not change anything you are taking.** This is the single most important line in this article. No part of this research applies to anyone's current treatment. **Be sceptical of anything sold on the back of it.** Early-stage research is a favourite hook for products with no evidence behind them. If something is being advertised to you as a drug-free diabetes fix, it is not this. **If your current plan is not working, say so.** High readings, frequent lows, side effects you are putting up with - these are all reasons for a review rather than reasons to wait. Your GP practice or diabetes team can change the plan. **Use your pharmacist for the medicine questions.** Timing, interactions, what to do about a missed dose, whether a side effect is expected. You do not need an appointment and you do not need to go through your GP first. **Get your reviews done.** Annual checks for eyes, feet, kidneys and blood pressure are the things that actually prevent the serious complications of diabetes. They are unglamorous and they work. **If you want to follow this research, follow it properly.** Look for news of human clinical trials. That is the stage where it either becomes real or quietly does not.
What to know
Researchers at ETH Zurich have built a battery-free implant that converts excess blood glucose into gluconate, which the body passes out in urine. A sensor and a smartphone switch it on when sugar is high and off when it returns to range. In diabetic mice it regulated blood sugar, produced weight loss, and worked reliably for six weeks without detectable tissue damage. It was published in Science. The essential caveat: it has never been tested in a human. The researchers' own next step is turning it into a medical device so that clinical testing can begin. Most treatments that work in mice do not make it through. The published news release also gives no figures for how much blood sugar or weight actually changed. The appeal is real - a system that acts only when there is surplus glucose has a different risk of causing low blood sugar than insulin does, and it adds no new drug to interact with existing medicines. But that appeal is theoretical until people are studied. For now: change nothing, keep your reviews, and take medicine questions to your pharmacist. Sources: ScienceDaily (ETH Zurich news release), 'New Diabetes Implant Uses Electricity to Lower Blood Sugar and Promote Weight Loss', 2 November 2026, https://www.sciencedaily.com/releases/2026/10/261031221151.htm; Maity D, Guha Ray P, Buchmann P, Charpin-El Hamri G, Fussenegger M, 'Wireless electrocatalytic closed-loop system for drug-free management of diabesity', Science, 2026; 394(6822), https://doi.org/10.1126/science.ady8560; NHS, 'Type 2 diabetes', https://www.nhs.uk/conditions/type-2-diabetes/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never start, stop or change diabetes treatment because of a news report on early research.
Related articles
Deaths reported abroad, none in the UK: the new monitoring advice for a Duchenne medicine
On 5 November 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) published new safety advice about a medicine called Duvyzat. Its other name is…
Nearly 3,000 eggs tested, one stamp code, and 78 illnesses going back to 2024
Laboratory work has now tied a long run of salmonella illness in the UK to eggs from one named producer in Ukraine. Reporting published on 2 November 2026 set…
The guidance used to stop at 17. Adults with this rare condition are now included
On 4 November 2026, the National Institute for Health and Care Excellence - NICE - updated its guidance on a medicine called setmelanotide, sold as Imcivree. T…